ALCON
15.12.2021 17:27:08 CET | Business Wire | Press release
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, continues its successful rollout of PRECISION1TM . The spherical lens is now available in key markets throughout Latin America and Asia, and PRECISION1 for Astigmatism is available in markets throughout Europe. PRECISION1 for Astigmatism and PRECISION1 sphere are also available throughout North America.
PRECISION1 contact lenses are designed to address the common reasons why 20% of new wearers drop out in the first three weeks: poor vision, poor comfort and handling issues.3 The lenses provide precise vision, long-lasting comfort and ease of handling to allow new wearers,1 especially those with long busy days, an exceptional lens-wearing experience.
Inspired from the water gradient lens material in DAILIES TOTAL1® , PRECISION1 is the first-and-only contact lens with Alcon’s proprietary SMARTSURFACE® Technology. This features a permanent, micro-thin, high-performance layer of moisture at the lens surface that helps support a stable tear film.4
A stable tear film is vital to visual performance and comfort, especially for contact lens wearers.5
“Reinforcing our mission to help people see brilliantly, we are proud of the PRECISION1 contact lens launch, designed for people with an on-the-go lifestyle, in many markets across the globe,” said Antoine Delgrange, Alcon Vice President for Vision Care International Marketing. “We understand the consumer journey can be challenging; so, as an added benefit, we are offering the opportunity for our customers to provide their new lens wearers with an exclusive activation program to make their introduction to contact lenses easy and enjoyable. The program includes resources to increase consumer confidence with their new lenses.”
“I think of PRECISION1 as the contact lens of the future. It’s so comfortable to wear and easy to fit that the wearing experience amazes my patients,” said Dr. Teodoro Tarud, optician and owner of Centro Óptico de la Costa, Columbia.*
The launch of PRECISION1 for Astigmatism provides a significant opportunity to attract new contact lens wearers. Studies show that 41% of patients have astigmatism that needs correction,6 but only 10% wear toric contact lenses.7 "Our patients love the comfort of PRECISION1! This is the best launch I have ever seen. We can fit more patient types now that toric and minus lenses are available," said Fiona Kavanagh, owner and optician at Jennings Opticians, Ireland.**
“We are committed to providing eye care professionals (ECPs) with a comprehensive portfolio of lens-wearing options based on the specific needs of their patients,” said Cheryl Donnelly, International Head of Professional Affairs at Alcon. “Now, with PRECISION1 and PRECISION1 for Astigmatism, ECPs and optical retailers can offer more lens wearers a next-generation contact lens with exceptional all-day performance.”
For more information, visit PRECISION1® One-Day Contact Lenses | PRECISION1® (myalcon.com)
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. In particular, our expectations could be affected by uncertainties regarding the success of our separation and spin-off from Novartis. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.
Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 23,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com .
* Teodoro Tarud is a paid Alcon consultant.
** Fiona Kavanagh is a paid Alcon consultant.
References
- Grant T, Tang A. A Survey of contact lens wearers and eye care professionals on satisfaction with a new smartsurface silicone hydrogel daily disposable contact lens. Clin Optom 2020;12:9–15.
- In a clinical study, wherein subjects were fitted with PRECISION1 for Astigmatism contact lenses (N=78 eyes); Alcon data on file, 2020.
- Sulley A, Young G, Hunt C, et al. Retention rates in new contact lens wearers. Eye & Contact Lens. 2018;44:S273-S282.
- In vitro analysis of verofilcon A contact lenses for surface properties; Alcon data on file 2019.
- Craig JP, Willcox MDP, Argueso P, et al. The TFOS international workshop on contact lens discomfort: Report of the contact lens interactions with tear film subcommittee. Invest Ophthalmol Vis Sci. 2013; 54:TFOS123-TFOS156.
- Luensmann D, Schaeffer J, Rumney N, et al. Spectacle prescriptions review to determine prevalence of ametropia and coverage of frequent replacement soft toric contact lenses. Contact Lens and Anterior Eye ; 2018; 41 (5); 412-420.
- Multi-Sponsor Surveys 2014 Gallup target market report.
Connect with us on
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005725/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
